Reduced lopinavir exposure during pregnancy.

  title={Reduced lopinavir exposure during pregnancy.},
  author={A. Stek and Mark M Mirochnick and Edmund Capparelli and Brookie Manning Dugan Best and Chengcheng Hu and Sandra K. Burchett and Carol Elgie and Diane T Holland and Elizabeth N Smith and Ruth E Tuomala and Amanda Cotter and Jennifer Suzanne Read},
  volume={20 15},
BACKGROUND Optimal antiretroviral exposure during pregnancy is critical for prevention of mother-to-child HIV transmission and for maternal health. Pregnancy can alter antiretroviral pharmacokinetics. Our objective was to describe lopinavir/ritonavir (LPV/r) pharmacokinetics during pregnancy. METHODS We performed intensive steady-state 12-h pharmacokinetic profiles of lopinavir and ritonavir (three capsules: LPV 400 mg/r 100 mg) at 30-36 weeks gestation and 6-12 weeks postpartum. Maternal and… CONTINUE READING